Abstract
The aim of this study is to report on the clinical safety and diagnostic efficacy of iobitridol (Xenetix®) in intravenous urography compared to iohexol (Omnipaque®) or iopamidol (Iopamiro®). A total of 120 patients underwent intravenous urography (ivu); 60 received Xenetix and 60 either Omnipaque (30 patients) or Iopamiro (30 patients) according to the center where they were treated. Clinical safety was assessed by the reporting of adverse events and diagnostic efficacy was evaluated. Warmth sensation was the most commonly reported adverse event. Two cases of nausea and vomiting were reported. Concerning diagnostic efficacy, 72–74% of the ivu examinations were rated good or excellent by the physician. These studies confirm that Xenetix is a suitable contrast agent for ivu.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
